Company Profile - Morphic Holding Inc
Introduction
Morphic Holding Inc (Morphic Therapeutic) is biopharmaceutical company that develops oral integrin therapies for the treatment of autoimmune, cardiovascular and metabolic diseases and fibrosis and cancer based on its Morphic integrin technology platform (MInT Platform). Its lead products candidate MORF - O57 (α4β7) is intended for the treatment of inflammatory bowel disease (IBD). It also developing Next Gen α4β7 Inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis. The company operates in Delaware and Massachusetts, the US. Morphic Therapeutic is headquartered in Waltham, Massachusetts, the US.
Company info
| Country (HQ): | United States |
| Sector: | Pharmaceuticals and Healthcare |
| Market Cap (US$ m): | 2,540 |
| Revenue (US$ m): | 71 (2022) |
Innovation ranking
Innovation score
Closest peers in the Pharmaceuticals and Healthcare sector
Innovation Ranking
Johnson & Johnson
United States
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd
Switzerland
Pharmaceuticals and Healthcare
Morphic Holding Inc
United States
Pharmaceuticals and Healthcare
EyeGate Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
Shin Poong Pharm Co Ltd
South Korea
Pharmaceuticals and Healthcare
Are you ranked? Get the Innovation Ranking Report
-
Company Ranking Report
- If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
- Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
- Contextualised information on the company's standing in relation to peers
- Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
- Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
- Rosettes
- Certificate of Achievement
- Press release
